AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02609945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolmitriptan
Description: Oral Tablet and Nasal Spray
Study NCT02469454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early insertion
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
Study NCT02469454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional insertion
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
Study NCT02429895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-122
Description: Injection
Study NCT03382938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: WOUND INFILTRATION IN CESAREAN SECTION
Study NCT02609945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-427 (zolmitriptan inhalation powder),
Description: Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
Study NCT03382938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: WOUND INFILTRATION IN CESAREAN SECTION
Study NCT03382938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine - Ropivacaine
Description: WOUND INFILTRATION IN CESAREAN SECTION
Study NCT03382938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0,9% saline
Description: placebo WOUND INFILTRATION IN CESAREAN SECTION
Study NCT03337074 — intervention group
Intervention type: OTHER
Intervention: Questionnaire, semen sample, fasting blood sample
Description: Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
Study NCT03337074 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants are asked to complete a questionnaire.
Study NCT03337074 — intervention group
Intervention type: OTHER
Intervention: Questionnaire, fasting blood sample
Description: Participants are asked to complete a questionnaire and provide a fasting blood sample.
Study NCT00310531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menostar (Estradiol, BAY86-5435)
Description: Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
Study NCT00310531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: Raloxifene tbl. (60 mg/day)
Study NCT02484963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Study NCT02484963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04358653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fall prevention exercise program
Description: The intervention protocol was starting with a 10 minute warm up (5 minutes circular walking combined with neck rotation in clockwise and counterclockwise fashion and 5 minutes upper and lower limp stretching exercises) and was followed by 30 minutes of exercises that were aiming to muscle strengthening, balance improvement and functionability enhancement. The muscle strengthening routine consisted of exercises both from standing and sitting position using an elastic band, heel and toe standing, upper limb strengthening using dumbbells. Balance training consisted of standing on one leg, shifting weight laterally from one foot to the other, staggered stance, side stepping. Functionalibility improvement was promoted through walking upstairs and downstairs, standing up from sitting to upright position. At the end a 5 minute cool down procedure was following consisting of circular walking, mild head movements and upper and lower body stretching.
Study NCT03566251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.
Study NCT03566251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional mobility
Description: Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.
Study NCT03566251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.
Study NCT03566251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk position sense
Description: Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
Study NCT01321268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)
Description: oral, twice daily in morning and evening for 6 months
Study NCT01321268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Viatmin E
Description: oral, twice daily in morning and evening for 6 months
Study NCT01846611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: 1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
Study NCT01846611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Description: 30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
Study NCT03962127 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01162967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: Standard dosage
Study NCT01162967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Study NCT00702741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondrogen
Description: Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
Study NCT00702741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intra-articular injection of Hyaluronan
Study NCT02584257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo Lupin albuterol HFA MDI
Study NCT02584257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo Lupin albuterol HFA MDI
Study NCT02584257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Lupin albuterol HFA MDI
Study NCT01846611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
Study NCT01846611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOXIL
Description: 50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
Study NCT02743650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
Study NCT01844609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Study Journal Club
Description: This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
Study NCT01844609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Journal Club
Description: This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
Study NCT01253759 — intervention group
Intervention type: PROCEDURE
Intervention: TTT + ICG-based PDT
Study NCT01505868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV
Study NCT01505868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01505868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02333695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Magnetic Stimulation
Description: Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
Study NCT00867451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention
Description: A structured sleep protocol is taught to parents, use of a white noise generator
Study NCT00867451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight >40mg will be given 6 mg at bedtime for two weeks
Study NCT03195088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 473494
Description: Solution for injection
Study NCT03195088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study NCT00935844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-901
Description: This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2.
Study NCT00947479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: continuous positive airway pressure (CPAP)
Description: After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
Study NCT03272607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing opportunities
Description: An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
Study NCT00866684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
Study NCT00866684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
Study NCT00866684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate
Description: Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
Study NCT00866684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
Study NCT00866684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
Study NCT04052594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475766 - IV
Description: Administered IV
Study NCT01895855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200
Description: Single dose; liquid suspension after reconstitution with buffer; 5x10\^8
Study NCT01895855 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03038633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Medical Food
Description: This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
Study NCT01387347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin beta 4
Description: A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
Study NCT01387347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
Study NCT04156776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
Study NCT04156776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Isolated Stretching
Description: The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
Study NCT04156776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
Study NCT03906045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF-MDI
Description: Budesonide, Glycopyrronium and Formoterol Fumarate.
Study NCT03168308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex 2 mg/kg
Study NCT03168308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine w/ Glycopyrrolate
Description: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
Study NCT02045576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sleep position trainer
Study NCT02045576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Appliance Therapy
Study NCT02951156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody
Study NCT02951156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Investigational, fully human IgG2 CD 137/4-1BB agonist
Study NCT02951156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: CD20-directed cytolytic antibody
Study NCT01884207 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT02951156 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: CD20-directed cytolytic antibody
Study NCT02951156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Antimetabolite antineoplastic agent and demethylation agent.
Study NCT02951156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Alkylating drug
Study NCT02951156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Alkylating drug
Study NCT02951156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Nucleoside analogue
Study NCT04052594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475766 - SC
Description: Administered SC
Study NCT02951156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Platinum-based drug
Study NCT03386942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab Ecteribulin
Description: Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
Study NCT02755324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: male Schistosoma mansoni cercariae
Description: Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
Study NCT03582020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menu plans
Description: menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
Study NCT03582020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: menu plans
Description: menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
Study NCT02245074 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sputum induction
Description: The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
Study NCT00277433 — intervention group
Intervention type: OTHER
Intervention: Buccal Swab
Description: collection of buccal swab
Study NCT01408979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 12 hours
Description: Magnesium sulfate, 1g/h, (10% solution), for 12 hours
Study NCT01408979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate 24 hours
Description: Magnesium sulfate, 1g/h, (10% solution), for 24 hours
Study NCT01946373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT01946373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT01946373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cells